NDC 0069-6002-01 - Octagam Immune Globulin (Human)
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 0069-6002
- Requested NDC
- 0069-6002-01
- Package NDCs from labels
- 0069-6002-01, 0069-6002-02
- Manufacturer
- Pfizer Laboratories Div Pfizer Inc
- Effective date
- 2024-01-26
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Octagam Immune Globulin (Human) - Pfizer Laboratories Div Pfizer Inc | Pfizer Laboratories Div Pfizer Inc | 2024-01-26 | PLASMA DERIVATIVE |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0069-6002-01 | Octagam Immune Globulin (Human) | 20 mL in 1 BOTTLE, GLASS | SOLUTION | 20 | 2 | |
| 0069-6002-02 | Octagam Immune Globulin (Human) | 1 in 1 CARTON | SOLUTION | 1 | 2 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0069-6002-01 | ML - Milliliter | 0069-6002 | 6a1d7beb-b380-4724-8d79-27a47ba886ed | 1 | 2023-12-05 |
| 0069-6002-02 | ML - Milliliter | 0069-6002 | af627cb5-21fd-448d-ba1a-054c4529091e | 1 | 2024-02-14 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ASCENIV | HUMAN IMMUNOGLOBULIN G | ADMA Biologics, Inc. | d74f4360-3b51-496c-96fb-84c3976958d2 | 2026-09-29 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| BIVIGAM | IMMUNE GLOBULIN INTRAVENOUS (HUMAN) 10% | ADMA Biologics, Inc. | a2244aa0-a6d0-11df-b385-0002a5d5c51b | 2026-09-29 | Boxed warning, Warnings, Adverse reactions | 1809421 1809414 66Y330CJHS |
| YIMMUGO | IMMUNE GLOBULIN INTRAVENOUS, HUMAN - DIRA | Kedrion Biopharma Inc | 50fc5ffc-49aa-51f2-e063-6294a90a59cf | 2026-07-15 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| HYQVIA | IMMUNE GLOBULIN INFUSION (HUMAN), 10% WITH RECOMBINANT HUMAN HYALURONIDASE | Takeda Pharmaceuticals America, Inc. | 7ca2c26f-4be2-48cd-be5b-486e350654ba | 2026-06-18 | Boxed warning, Warnings, Adverse reactions | 1809444 1809421 1809414 1809539 |
| Privigen | HUMAN IMMUNOGLOBULIN G | CSL Behring AG | 7e5649da-75be-4a42-8eeb-4aeba562c401 | 2026-05-04 | Boxed warning, Warnings, Adverse reactions | 1809444 1809421 1809414 66Y330CJHS |
| YIMMUGO | IMMUNE GLOBULIN INTRAVENOUS, HUMAN - DIRA | Biotest AG | 77aaac18-f2af-46c4-8f65-b15be1cec3c2 | 2026-03-01 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| QIVIGY kthm | HUMAN IMMUNOGLOBULIN G | Kedrion S.p.A. | 6f1933e0-240f-48f4-b246-8a30e63a4160 | 2026-02-02 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| GAMMAGARD Liquid | IMMUNE GLOBULIN INFUSION (HUMAN) | Takeda Pharmaceuticals America, Inc. | 9d42adca-0dd7-4df7-864d-5a7feee52130 | 2025-12-10 | Boxed warning, Warnings, Adverse reactions | 1809444 1809421 1809414 1809539 66Y330CJHS |
| CUVITRU | IMMUNE GLOBULIN SUBCUTANEOUS (HUMAN) | Takeda Pharmaceuticals America, Inc. | 9aad7ec9-6097-4805-8f1b-898bec35f218 | 2025-11-25 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| GAMMAGARD Liquid ERC | IMMUNE GLOBULIN INFUSION (HUMAN) | Takeda Pharmaceuticals America, Inc. | 1341fd31-0754-47f0-a4d6-7255056b6541 | 2025-10-30 | Boxed warning, Warnings, Adverse reactions | 1809421 1809414 66Y330CJHS |
| Gammaplex | HUMAN IMMUNOGLOBULIN G | Bio Products Laboratory Ltd | 2098af41-aec7-4af7-98bb-54f8ab55f30e | 2025-10-23 | Boxed warning, Warnings, Adverse reactions | 1809444 1809421 1809414 66Y330CJHS |
| Alyglo | HUMAN IMMUNOGLOBULIN G | GC Biopharma Corp. | fb97b3ec-29ee-4df1-aa99-c23e57a21228 | 2025-06-05 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| Panzyga | IMMUNE GLOBULIN INTRAVENOUS (HUMAN) | Octapharma USA Inc | 9306c5f7-ddf9-5190-d0c1-31ba9ca2d0e0 | 2025-05-08 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| Panzyga | IMMUNE GLOBULIN INTRAVENOUS (HUMAN) | Pfizer Laboratories Div Pfizer Inc | e2cc5ddf-119e-ade3-79c2-c712cfbee099 | 2025-05-08 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| Cutaquig | IMMUNOGLOBULIN G | Pfizer Laboratories Div Pfizer Inc | f199187a-de4e-2047-0aee-b6d93390b3d2 | 2025-03-24 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| Octagam Immune Globulin (Human) | IMMUNE GLOBULIN | Pfizer Laboratories Div Pfizer Inc | fb07257b-e5e2-64c8-666c-65009f0aa604 | 2024-01-29 | Boxed warning, Warnings, Adverse reactions | BLA125062 66Y330CJHS |
| Octagam Immune Globulin (Human) | IMMUNE GLOBULIN | Pfizer Laboratories Div Pfizer Inc | eb4c342b-122c-0072-1428-1747882e6c00 | 2024-01-26 | Boxed warning, Warnings, Adverse reactions | BLA125062 0069-6111-01 0069-6550-02 0069-6550-01 0069-6002-02 0069-6002-01 0069-6339-02 0069-6339-01 0069-6111-02 0069-6237-01 0069-6237-02 0069-6339 0069-6550 0069-6002 0069-6237 0069-6111 00069600201 1809503 2170634 1809444 1809499 1809502 1809501 1809421 1809497 1809414 1809539 86003c7c-517c-9c41-8960-cace21be471c eb4c342b-122c-0072-1428-1747882e6c00 66Y330CJHS |
| Hizentra | HUMAN IMMUNOGLOBULIN G | CSL Behring AG | 7b58f5ff-0316-49a3-b585-1f6003ddb953 | 2023-04-20 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| Octagam Immune Globulin (Human) | IMMUNE GLOBULIN | Octapharma USA Inc | de00abeb-d635-eddc-b603-10708ecef5aa | 2022-04-19 | Boxed warning, Warnings, Adverse reactions | BLA125062 66Y330CJHS |
| Octagam Immune Globulin (Human) | IMMUNE GLOBULIN | Octapharma USA Inc | a36a12dc-16be-b135-466f-393954f428a7 | 2022-04-08 | Boxed warning, Warnings, Adverse reactions | BLA125062 1809503 2170634 1809444 1809499 1809502 1809501 1809421 1809497 1809414 1809539 66Y330CJHS |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.